FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2017 (May 2, 2017)

Alnylam Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-36407

77-0602661

(State or Other Juris-

diction of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

300 Third Street, Cambridge, MA	02142
(Address of Principal Executive Offices)	(Zip Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ⃞

On May 5, 2017, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2017. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The 2017 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company was held on May 2, 2017. As of March 10, 2017, the record date for the Annual Meeting, 86,052,558 shares of the Company’s common stock were issued and outstanding. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

1. The Company’s stockholders re-elected the four persons listed below as Class I directors, each to serve until the Company’s 2020 annual meeting of stockholders and until his successor is duly elected and qualified. The voting results were as follows:

	Votes For	Votes Against	Abstentions	Broker Non-Votes
Michael W. Bonney	72,449,044	1,013,752	31,532	5,404,213
John M. Maraganore, Ph.D.	72,672,900	788,748	32,680	5,404,213
Paul R. Schimmel, Ph.D.	73,153,864	308,969	31,495	5,404,213
Phillip A. Sharp, Ph.D.	66,585,685	6,877,420	31,223	5,404,213

The terms of office of the following directors continued after the Annual Meeting:

Dennis A. Ausiello, M.D.

John K. Clarke

Marsha H. Fanucci

Steven M. Paul, M.D.

David E.I. Pyott

Amy W. Schulman

Kevin P. Starr

2. The Company’s stockholders approved the Company’s Second Amended and Restated 2009 Stock Incentive Plan. The voting results were as follows:

3. The Company’s stockholders approved the Company’s Amended and Restated 2004 Employee Stock Purchase Plan. The voting results were as follows:

4. The Company’s stockholders approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers. The voting results were as follows:

5. The Company’s stockholders recommended, in a non-binding advisory vote, a frequency of every One Year for future advisory stockholder votes on the compensation of the Company’s named executive officers. The voting results were as follows:

The Company currently intends to hold an advisory vote on the compensation of its named executive officers every year until the next required advisory vote on the frequency of holding the advisory vote on named executive officer compensation.

6. The Company’s stockholders ratified the appointment by the Company’s Board of Directors of PricewaterhouseCoopers LLP as the Company’s independent auditors for the fiscal year ending December 31, 2017. The voting results were as follows:

The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 5, 2017	ALNYLAM PHARMACEUTICALS, INC.

	By:	/s/ Michael P. Mason
		Michael P. Mason
		Vice President, Finance and Treasurer

Exhibit No.		Description

99.1		Press Release dated May 5, 2017

One Year		Two Years		Three Years		Abstentions		Broker Non-Votes
70,891,792		305,069		2,262,394		35,073		5,404,213